Exploring the metabolic adverse effects induced by Nilotinib in adult patients diagnosed with Chronic Myeloid Leukaemia – A Scoping Review
DOI:
https://doi.org/10.22024/UniKent/03/ajpp.1354Abstract
Background: Chronic myeloid leukaemia (CML), characterised by the BCR-ABL1 gene mutation, is a myeloproliferative condition primarily managed with tyrosine kinase inhibitors (TKIs), such as 2nd generation Nilotinib. However, the wide range of therapies available, alongside the generally favourable outcomes, may lead to the misconception that CML is a straightforward disease to manage. This attitude can expose high-risk patients to delayed treatment responses, insufficient attention to toxicity concerns and poor outcomes. Thus, a scoping review was conducted to address these concerns, particularly the metabolic safety profile of Nilotinib.
Methods: This review utilised the PRISMA Extension for Scoping Review (PRISMA-ScR) checklist as a foundation for research. A systematic literature search was conducted across multiple databases, and these studies were inputted into Rayyan software. Fifteen studies met the inclusion criteria following a comprehensive review process and data were synthesised through thematic analysis. The papers consisted primarily of observational cohort studies, however there was also 1 randomised controlled trial (RCT) and 1 case report.
Results: All the studies observed adverse Nilotinib-induced metabolic changes, and most commented on the long-term cardiovascular implications of these adverse effects. One of the most prevalent adverse effects was hyperglycaemia; according to several studies, up to 11% of patients experienced grade 3/4 hyperglycaemic episodes and elevated fasting glucose levels. Significant rises in HbA1c, however, were rare. Within three to six months of starting medication, lipid abnormalities such as increased LDL, HDL, and total cholesterol were noted, indicating the necessity of proactive lipid monitoring. Although no clear connection to pancreatitis was found, elevated pancreatic enzymes were also reported. Cardiovascular implications, including increased risk of diabetes, dyslipidaemia, and peripheral arterial disease, were evident, with higher cumulative CV events in patients on prolonged Nilotinib therapy, particularly at higher doses.
Conclusions: Findings highlight the need for robust cardiovascular risk assessment and careful monitoring of Nilotinib's metabolic effects to reduce long-term risks.
Downloads
Published
How to Cite
Issue
Section
License
© The Author(s). 2018 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
AJPP requests that, as the creator(s)/author(s) of the manuscript you are submitting, that you assign certain rights to the manuscript to the AJPP in exchange for undertaking to publish the article in electronic form and, in general, to pursue its dissemination throughout the world. The rights the AJPP requests are:
- The right to publish the article in electronic form or in any other form it may choose that is in keeping with its role as a scholarly journal with the goal of disseminating the work as widely as possible;
- The right to be the sole publisher of the article for a period of 12 months;
- The right to make the article available to the public within a period of not more than 24 months, as determined by relevant journal staff of the AJPP;
- The right to grant republication rights to itself or others in print, electronic, or any other form, with any revenues accrued to be shared equally between the author(s) and the journal;
- The right to administer permission to use portions of the article as requested by others, seeking recompense when the AJPP sees it as warranted;
- The right to seek or take advantage of opportunities to have the article included in a database aimed at increasing awareness of it;
- As the author(s), the AJPP wishes you to retain the right to republish the article, with acknowledgement of the AJPP as the original publisher, in whole or in part, in any other pbulication of your own, including any anthology that you might edit with up to three others;
- As the author(s), the AJPP wishes you to retain the right to place the article on your personal Web page or respository of your university or institution. The AJPP askes that you include this notice: A fully edited, peer-reviewed version of this article was first published by the Advanced Journal of Professional Practice, <Year>, <Volume>, <Issue>, <Page Numbers>.
- You retain the right to unrestricted use of your paper for yourself or for your own teaching purposes.
BY AGREEING TO THE FOREGOING, YOU CONFIRM THAT THE MANUSCRIPT YOU ARE SUBMITTING HAS NOT BEEN PUBLISHED ELSEWHERE IN WHOLE OR IN PART, AND THAT NO AGREEMENT TO PUBLISH IS OUTSTANDING.
SHOULD THE ARTICLE CONTAIN MATERIAL WHICH REQUIRES WRITTEN PERMISSION FOR INCLUSION, YOU AGREE THAT IT IS YOUR OBLIGATION IN LAW TO IDENTIFY SUCH MATERIAL TO THE EDITOR OF THE AJPP AND TO OBTAIN SUCH PERMISSION. THE AJPP WILL NOT PAY ANY PERMISSION FEES. SHOULD THE AJPP BE OF THE OPINION THAT SUCH PERMISSION IS NECESSARY, IT WILL REQUIRE YOU TO PURSUE SUCH PERMISSSION PRIOR TO PUBLICATION.
AS AUTHOR(S), YOU WARRANT THAT THE ARTICLE BEING SUBMITTED IS ORIGINAL TO YOU.
Provided the foregoing terms are satisfactory, and that you are in agreement with them, please indicate your acceptance by checking the appropriate box and proceed with your submission.
